Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Ovarian01: T-DXd + bevacizumab vs bevacizumab maintenance in HER2-expressing ovarian cancer
jRCT2051240289Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-Free Survival by Blinded Independent Central Review in HER2 IHC 3+/2+ population. Started Mar 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2051240289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240289.